-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the current situation of changes in the pharmaceutical market, the executives of pharmaceutical companies are changing frequently
.
Entering 2022, news about the big change of executives of pharmaceutical companies is still coming out
.
On January 13, Sunshine Guojian issued 9 announcements in a row, mainly related to the company's annual report performance forecast and the executive change, which attracted great attention in the industry
.
Among them, the "Announcement on the Resignation of Directors, Senior Managers and Core Technicians" shows that recently, Mr.
ZHU ZHENPING, the company's director/deputy general manager/R&D leader/core technician, applied to resign from the fourth session of the company's board of directors due to work adjustment.
Non-independent director/deputy general manager/head of R&D will no longer hold any position in the company after resignation
.
It is understood that Mr.
ZHU ZHENPING served as Executive Vice President of Kadmon Corporation, Head of Global Biopharmaceutical R&D, President of Kadmon China, and Vice President of Novartis.
He has more than 30 years of experience in the field of therapeutic antibody research and development, including 23 years in the international biopharmaceutical industry.
R&D and management experience
.
Until June 2019, Mr.
ZHU ZHENPING joined Sunshine Guojian as director, deputy general manager, head of R&D, and core technical staff of the company
.
During his tenure, he was mainly responsible for the strategic layout of the company's R&D pipeline and participated in the company's research and development of new drugs for the treatment of tumors, autoimmune diseases and ophthalmic diseases; so far, the company has applied for a total of 185 valid patent applications (including 4 utility model patents) , a total of 64 authorized and valid patents (including 4 utility model patents), of which Mr.
ZHU ZHENPING applied and valid for a total of 99 patent applications as a non-single inventor during his tenure, 0 authorized and valid patents, and the aforementioned All rights to patent applications belong to the company
.
As of the disclosure date of this announcement, Mr.
ZHU ZHENPING does not directly or indirectly hold any shares of the company
.
Sunshine Guojian expects that Mr.
ZHU ZHENPING's resignation will not affect the normal operation of the company's board of directors
.
It is worth mentioning that after this change, the number of core technical personnel of Sunshine Guojian has been reduced from 3 to 2.
The incumbents are Huang Haomin and Weng Zhibing
.
However, the company said that Sunshine Guojian's existing core technical personnel can support the sustainable development of the company's core technology in the future
.
On the same day, Sunshine Guojian issued the "Announcement on By-election of Non-Independent Directors".
After review by the nomination committee of the board of directors, the board of directors nominated Ms.
Liu Yanli as a candidate for the non-independent director of the fourth session of the board of directors.
From the date of deliberation and approval to the date of expiry of the term of office of the current board of directors
.
The attachment shows that Ms.
Liu Yanli worked for 3SBio and Shenyang 3SBio and has rich experience in capital operation, corporate governance, information disclosure, law, investor relations, investment project management, etc.
; since June 2019, she has been the vice president of the company Manager, Secretary of the Board of Directors
.
As of the disclosure date of this announcement, Ms.
Liu Yanli indirectly held 3,811,600 shares of the company, accounting for 0.
62% of the company's total shares
.
In addition, the 2021 annual performance pre-earning announcement released by Sunshine Guojian shows that it is expected to achieve annual revenue of 900 million yuan to 1 billion yuan, a year-on-year increase of 37.
40% to 52.
67%; net profit attributable to the parent is 18 million yuan to 22 million yuan , to achieve a turnaround
.
In this regard, the company stated that the key to turning losses is that the core product Yisaipu has achieved "price-for-volume"
.
However, due to the company's continuous increase in R&D investment (expected to be between 420 million and 480 million yuan), Sunshine Guojian expects that its profit in 2021 will be at a low level
.
.
Entering 2022, news about the big change of executives of pharmaceutical companies is still coming out
.
On January 13, Sunshine Guojian issued 9 announcements in a row, mainly related to the company's annual report performance forecast and the executive change, which attracted great attention in the industry
.
Among them, the "Announcement on the Resignation of Directors, Senior Managers and Core Technicians" shows that recently, Mr.
ZHU ZHENPING, the company's director/deputy general manager/R&D leader/core technician, applied to resign from the fourth session of the company's board of directors due to work adjustment.
Non-independent director/deputy general manager/head of R&D will no longer hold any position in the company after resignation
.
It is understood that Mr.
ZHU ZHENPING served as Executive Vice President of Kadmon Corporation, Head of Global Biopharmaceutical R&D, President of Kadmon China, and Vice President of Novartis.
He has more than 30 years of experience in the field of therapeutic antibody research and development, including 23 years in the international biopharmaceutical industry.
R&D and management experience
.
Until June 2019, Mr.
ZHU ZHENPING joined Sunshine Guojian as director, deputy general manager, head of R&D, and core technical staff of the company
.
During his tenure, he was mainly responsible for the strategic layout of the company's R&D pipeline and participated in the company's research and development of new drugs for the treatment of tumors, autoimmune diseases and ophthalmic diseases; so far, the company has applied for a total of 185 valid patent applications (including 4 utility model patents) , a total of 64 authorized and valid patents (including 4 utility model patents), of which Mr.
ZHU ZHENPING applied and valid for a total of 99 patent applications as a non-single inventor during his tenure, 0 authorized and valid patents, and the aforementioned All rights to patent applications belong to the company
.
As of the disclosure date of this announcement, Mr.
ZHU ZHENPING does not directly or indirectly hold any shares of the company
.
Sunshine Guojian expects that Mr.
ZHU ZHENPING's resignation will not affect the normal operation of the company's board of directors
.
It is worth mentioning that after this change, the number of core technical personnel of Sunshine Guojian has been reduced from 3 to 2.
The incumbents are Huang Haomin and Weng Zhibing
.
However, the company said that Sunshine Guojian's existing core technical personnel can support the sustainable development of the company's core technology in the future
.
On the same day, Sunshine Guojian issued the "Announcement on By-election of Non-Independent Directors".
After review by the nomination committee of the board of directors, the board of directors nominated Ms.
Liu Yanli as a candidate for the non-independent director of the fourth session of the board of directors.
From the date of deliberation and approval to the date of expiry of the term of office of the current board of directors
.
The attachment shows that Ms.
Liu Yanli worked for 3SBio and Shenyang 3SBio and has rich experience in capital operation, corporate governance, information disclosure, law, investor relations, investment project management, etc.
; since June 2019, she has been the vice president of the company Manager, Secretary of the Board of Directors
.
As of the disclosure date of this announcement, Ms.
Liu Yanli indirectly held 3,811,600 shares of the company, accounting for 0.
62% of the company's total shares
.
In addition, the 2021 annual performance pre-earning announcement released by Sunshine Guojian shows that it is expected to achieve annual revenue of 900 million yuan to 1 billion yuan, a year-on-year increase of 37.
40% to 52.
67%; net profit attributable to the parent is 18 million yuan to 22 million yuan , to achieve a turnaround
.
In this regard, the company stated that the key to turning losses is that the core product Yisaipu has achieved "price-for-volume"
.
However, due to the company's continuous increase in R&D investment (expected to be between 420 million and 480 million yuan), Sunshine Guojian expects that its profit in 2021 will be at a low level
.
